Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn GlobeNewswire - Tue Dec 23, 4:57PM CST

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% GlobeNewswire - Thu Dec 4, 6:00AM CST

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Tue Dec 2, 7:00AM CST

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results GlobeNewswire - Thu Nov 13, 5:45AM CST

Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing GlobeNewswire - Fri Nov 7, 7:00AM CST

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Launches Zelsuvmi for Skin Condition Tipranks - Wed Oct 15, 7:30AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pelthos Therapeutics...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum GlobeNewswire - Thu Oct 9, 7:00AM CDT

The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversation Molluscum is a highly contagious skin infection...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire - Mon Sep 8, 7:30AM CDT

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference GlobeNewswire - Tue Sep 2, 7:00AM CDT

DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative...

PTHS : 26.98 (+0.82%)
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update GlobeNewswire - Mon Aug 18, 7:00AM CDT

Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025 Strong physician response following successful launch of ZELSUVMI™...

PTHS : 26.98 (+0.82%)

Barchart Exclusives

2 Dividend Kings Quietly Beating the Market This Year Barchart - Tue Dec 23, 6:30PM CST
These two are the calm outperformers that might have been overlooked. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot